Document 0491
 DOCN  M9650491
 TI    L-cycloserine, an inhibitor of sphingolipid biosynthesis, inhibits HIV-1
       cytopathic effects, replication, and infectivity.
 DT    9605
 AU    Mizrachi Y; Lev M; Harish Z; Sundaram SK; Rubinstein A; Department of
       Pediatrics, Microbiology and Immunology, Albert; Einstein College of
       Medicine, Bronx, NY 10461, USA.
 SO    J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Feb 1;11(2):137-41.
       Unique Identifier : AIDSLINE MED/96147313
 AB    Drugs that reduce viral production or prevent viral spread by
       interference with the host's cellular components are unlikely to induce
       resistance, in contrast to treatment modalities that interact with the
       HIV-1 life cycle. Two features make L-cycloserine (L-CS) a candidate
       drug of this kind: (a) L-CS is a potent inhibitor of the sphingolipid
       pathway (b) sphingolipids, galactocerebrosides, and sulfatides have been
       shown, by others, to bind gp120. In a feasibility and efficacy study, we
       have found that L-CS inhibits HIV-1 replication in a CD4+ lymphoid cell
       line (CEM) as documented by the reduction of syncytium formation, the
       number of HIV-1 infected cells, and p24 protein production. This
       observation may lead to a new strategy for the treatment of HIV-1
       infection.
 DE    Antimetabolites/*PHARMACOLOGY  Cell Line  Cycloserine/*PHARMACOLOGY
       Cytopathogenic Effect, Viral/DRUG EFFECTS  CD4-Positive
       T-Lymphocytes/PHYSIOLOGY/VIROLOGY  Fluorescent Antibody Technique  Giant
       Cells  Human  HIV Core Protein p24/BIOSYNTHESIS  HIV-1/*DRUG
       EFFECTS/PHYSIOLOGY  Sphingolipids/*ANTAGONISTS & INHIB/BIOSYNTHESIS
       Support, Non-U.S. Gov't  Support, U.S. Gov't, P.H.S.  Virus
       Replication/*DRUG EFFECTS/PHYSIOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).